{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T03:20:27Z","timestamp":1785295227033,"version":"3.55.0"},"reference-count":32,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T00:00:00Z","timestamp":1613433600000},"content-version":"unspecified","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001922","name":"Efficacy and Mechanism Evaluation Programme","doi-asserted-by":"publisher","award":["14\/150\/85"],"award-info":[{"award-number":["14\/150\/85"]}],"id":[{"id":"10.13039\/501100001922","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2021,1,25]]},"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>In 2013, a single-centre study reported the safe use of esmolol in patients with septic shock and tachycardia who required vasopressor therapy for more than 24 hours. Although not powered to detect a change in mortality, marked improvements were seen in survival (adjusted HR, 0.39; 95%\u2009CI, 0.26 to 0.59; p&lt;0.001). Beta blockers are one of the most studied groups of drugs but their effect in septic shock is poorly understood; proposed mechanisms include not only the modulation of cardiac function but also immunomodulation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>STRESS-L is a randomised, open-label, non-blinded clinical trial which is enrolling a total of 340 patients with septic shock as defined by Sepsis-3 consensus definition and a tachycardia (heart rate \u226595\u2009beats per minute (bpm)) after vasopressor treatment of at least 24 hours. Standard randomisation (1:1 ratio) allocates patients to receive usual care (according to international standards) versus usual care and a continuous landiolol infusion to reduce the heart rate between 80 and 94 bpm. The primary endpoint is the mean Sequential Organ Failure Assessment score over 14 days from entry into the trial and while in intensive care unit. Results will inform current clinical practice guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>This trial has clinical trial authorisation from the UK competent authority, the Medicines and Healthcare products Regulatory Agency, and has been approved by the East of England-Essex Research Ethics Committee (reference: 17\/EE\/0368).<\/jats:p>\n                    <jats:p>The results of the trial will be reported first to trial collaborators. The main report will be drafted by the trial coordinating team, and the final version will be agreed by the Trial Steering Committee before submission for publication, on behalf of the collaboration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Registration<\/jats:title>\n                    <jats:p>\n                      The trial is funded by the National Institute for Health Research Efficacy and Mechanism Evaluation (EME) (Project Number: EME-14\/150\/85) and registered\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"ISRCTN12600919\">ISRCTN12600919<\/jats:ext-link>\n                      and EudraCT: 2017-001785-14.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2020-043194","type":"journal-article","created":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T04:27:52Z","timestamp":1613536072000},"page":"e043194","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":11,"title":["Study into the reversal of septic shock with landiolol (beta blockade): STRESS-L Study protocol for a randomised trial"],"prefix":"10.1136","volume":"11","author":[{"given":"Ranjit","family":"Lall","sequence":"first","affiliation":[{"name":"Warwick Clinical Trials Unit, University of Warwick, Coventry, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipesh","family":"Mistry","sequence":"additional","affiliation":[{"name":"Warwick Clinical Trials Unit, University of Warwick, Coventry, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Skilton","sequence":"additional","affiliation":[{"name":"Warwick Clinical Trials Unit, University of Warwick, Coventry, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nafisa","family":"Boota","sequence":"additional","affiliation":[{"name":"Leicester Clinical Trials Unit, Leicester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Regan","sequence":"additional","affiliation":[{"name":"Warwick Clinical Trials Unit, University of Warwick, Coventry, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0344-5403","authenticated-orcid":false,"given":"Julian","family":"Bion","sequence":"additional","affiliation":[{"name":"Intensive Care Medicine, University of Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Gates","sequence":"additional","affiliation":[{"name":"Warwick Clinical Trials Unit, University of Warwick, Coventry, UK"},{"name":"Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony C","family":"Gordon","sequence":"additional","affiliation":[{"name":"Division of Anaesthetics, Pain Medicine and Intensive Care, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Lord","sequence":"additional","affiliation":[{"name":"NIHR Surgical Reconstruction and Microbiology Research Centre, University of Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3283-1947","authenticated-orcid":false,"given":"Daniel Francis","family":"McAuley","sequence":"additional","affiliation":[{"name":"Centre for Experimental Medicine, Queen\"s University Belfast, Belfast, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Perkins","sequence":"additional","affiliation":[{"name":"Warwick Clinical Trials Unit, University of Warwick, Coventry, UK"},{"name":"University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mervyn","family":"Singer","sequence":"additional","affiliation":[{"name":"Bloomsbury Institute of Intensive Care Medicine, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duncan","family":"Young","sequence":"additional","affiliation":[{"name":"Kadoorie Centre for Critical Care Research, Nuffield Division of Anaesthesia, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4387-3421","authenticated-orcid":false,"given":"Tony","family":"Whitehouse","sequence":"additional","affiliation":[{"name":"Department of Critical Care and Anaesthesia, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK"},{"name":"Institute of Inflammation and Aging, University of Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,2,16]]},"reference":[{"key":"2025120520134752000_11.2.e043194.1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.278477"},{"key":"2025120520134752000_11.2.e043194.2","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1515\/jccm-2015-0027","article-title":"Cardiac arrhythmias in a septic ICU population: a review","volume":"1","author":"Schwartz","year":"2015","journal-title":"J Crit Care Med"},{"key":"2025120520134752000_11.2.e043194.3","doi-asserted-by":"publisher","DOI":"10.1097\/01.CCM.0000178181.91250.99"},{"key":"2025120520134752000_11.2.e043194.4","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/CCM.0000000000002065","article-title":"Relative bradycardia in patients with septic shock requiring vasopressor therapy","volume":"45","author":"Beesley","year":"2017","journal-title":"Crit Care Med"},{"key":"2025120520134752000_11.2.e043194.5","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-012-2769-8"},{"key":"2025120520134752000_11.2.e043194.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199406163302404"},{"key":"2025120520134752000_11.2.e043194.7","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/00000658-196901000-00007","article-title":"The treatment of endotoxin shock by beta adrenergic blockade","volume":"169","author":"Berk","year":"1969","journal-title":"Ann Surg"},{"key":"2025120520134752000_11.2.e043194.8","doi-asserted-by":"publisher","DOI":"10.1097\/01.CCM.0000182796.11329.3B"},{"key":"2025120520134752000_11.2.e043194.9","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-011-2236-y"},{"key":"2025120520134752000_11.2.e043194.10","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e3181c03dfa"},{"key":"2025120520134752000_11.2.e043194.11","doi-asserted-by":"publisher","DOI":"10.1097\/SHK.0b013e3181863689"},{"key":"2025120520134752000_11.2.e043194.12","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1164\/rccm.202002-0339OC","article-title":"Norepinephrine dysregulates the immune response and compromises host defense during sepsis","volume":"202","author":"Stolk","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"2025120520134752000_11.2.e043194.13","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1007\/s00508-012-0209-y","article-title":"Concomitant use of beta-1 adrenoreceptor blocker and norepinephrine in patients with septic shock","volume":"124","author":"Balik","year":"2012","journal-title":"Wien Klin Wochenschr"},{"key":"2025120520134752000_11.2.e043194.14","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1185\/03007995.2015.1062357","article-title":"Beta-blocker use in severe sepsis and septic shock: a systematic review","volume":"31","author":"Sanfilippo","year":"2015","journal-title":"Curr Med Res Opin"},{"key":"2025120520134752000_11.2.e043194.15","doi-asserted-by":"publisher","DOI":"10.1186\/cc8026"},{"key":"2025120520134752000_11.2.e043194.16","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2000.108733"},{"key":"2025120520134752000_11.2.e043194.17","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1248\/cpb.40.1462","article-title":"Development of a highly cardioselective ultra short-acting beta-blocker, ONO-1101","volume":"40","author":"Iguchi","year":"1992","journal-title":"Chem Pharm Bull"},{"key":"2025120520134752000_11.2.e043194.18","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00126839-200506060-00006","article-title":"Influence of hepatic impairment on the pharmacokinetics and pharmacodynamics of landiolol hydrochloride, an ultra-short-acting beta1-blocker","volume":"6","author":"Takahata","year":"2005","journal-title":"Drugs R D"},{"key":"2025120520134752000_11.2.e043194.19","doi-asserted-by":"crossref","unstructured":"Seki Y , Jesmin S , Shimojo N . Significant reversal of cardiac upregulated endothelin-1 system in a rat model of sepsis by landiolol hydrochloride. Life Sci 2014.","DOI":"10.1016\/j.lfs.2014.04.005"},{"key":"2025120520134752000_11.2.e043194.20","doi-asserted-by":"crossref","DOI":"10.1213\/01.ANE.0000140814.28118.6F","article-title":"Successful management of tachycardiac atrial fibrillation in a septic patient with landiolol","volume":"100","author":"Yoshida","year":"2005","journal-title":"Anesth Analg"},{"key":"2025120520134752000_11.2.e043194.21","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2017-222268","article-title":"Landiolol is effective for the treatment of tachycardia-induced cardiogenic shock in patients during septic shock therapy","volume":"2017","author":"Arita","year":"2017","journal-title":"BMJ Case Rep"},{"key":"2025120520134752000_11.2.e043194.22","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S2213-2600(20)30037-0","article-title":"Efficacy and safety of landiolol, an ultra-short-acting \u03b21-selective antagonist, for treatment of sepsis-related tachyarrhythmia (J-Land 3S): a multicentre, open-label, randomised controlled trial","volume":"8","author":"Kakihana","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2025120520134752000_11.2.e043194.23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e7586"},{"key":"2025120520134752000_11.2.e043194.24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c869"},{"key":"2025120520134752000_11.2.e043194.25","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.0287"},{"key":"2025120520134752000_11.2.e043194.26","doi-asserted-by":"publisher","DOI":"10.1097\/01.CCM.0000114827.93410.D8"},{"key":"2025120520134752000_11.2.e043194.27","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e31818b9153"},{"key":"2025120520134752000_11.2.e043194.28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609409"},{"key":"2025120520134752000_11.2.e043194.29","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-015-3757-6"},{"key":"2025120520134752000_11.2.e043194.30","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1056\/NEJMoa1705835","article-title":"Adjunctive glucocorticoid therapy in patients with septic shock","volume":"378","author":"Venkatesh","year":"2018","journal-title":"N Engl J Med Overseas Ed"},{"key":"2025120520134752000_11.2.e043194.31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1202290"},{"key":"2025120520134752000_11.2.e043194.32","doi-asserted-by":"crossref","unstructured":"Calfee CS , Janz DR , Bernard GR . Distinct molecular phenotypes of direct versus indirect ARDS in single and multi-center studies. Chest 2014.","DOI":"10.1378\/chest.14-2454"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2020-043194","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T04:13:54Z","timestamp":1764994434000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2020-043194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":32,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2,16]]},"published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10.1136\/bmjopen-2020-043194"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2020-043194","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2]]}}}